Natera (NASDAQ:NTRA) Price Target Raised to $200.00 at Sanford C. Bernstein

Natera (NASDAQ:NTRA) had its price objective hoisted by equities researchers at Sanford C. Bernstein from $160.00 to $200.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Sanford C. Bernstein’s price target indicates a potential upside of 15.16% from the company’s current price.

NTRA has been the topic of several other reports. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. TD Cowen raised their target price on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Canaccord Genuity Group lifted their target price on shares of Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. The Goldman Sachs Group increased their price target on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Finally, Leerink Partners lifted their price objective on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and a consensus target price of $158.00.

Natera Price Performance

NASDAQ:NTRA traded down $2.94 during mid-day trading on Friday, hitting $173.67. The company’s stock had a trading volume of 877,812 shares, compared to its average volume of 1,123,150. The company has a market capitalization of $22.93 billion, a price-to-earnings ratio of -98.68 and a beta of 1.65. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera has a fifty-two week low of $59.80 and a fifty-two week high of $177.00. The stock has a fifty day moving average of $159.12 and a 200-day moving average of $131.68.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same quarter last year, the company earned ($0.95) EPS. Natera’s revenue was up 63.9% on a year-over-year basis. As a group, equities analysts forecast that Natera will post -1.61 EPS for the current fiscal year.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 496 shares of the firm’s stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $119.09, for a total value of $59,068.64. Following the completion of the sale, the chief financial officer now directly owns 74,314 shares in the company, valued at approximately $8,850,054.26. This trade represents a 0.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Solomon Moshkevich sold 256 shares of the firm’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total value of $30,737.92. Following the completion of the sale, the insider now directly owns 111,891 shares of the company’s stock, valued at approximately $13,434,752.37. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 127,932 shares of company stock valued at $20,635,430 over the last three months. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Natera

Several hedge funds and other institutional investors have recently modified their holdings of NTRA. TD Asset Management Inc acquired a new stake in Natera during the 2nd quarter worth approximately $1,235,000. Quest Partners LLC boosted its holdings in Natera by 22,861.5% in the 2nd quarter. Quest Partners LLC now owns 2,985 shares of the medical research company’s stock valued at $323,000 after purchasing an additional 2,972 shares during the period. Headlands Technologies LLC acquired a new position in shares of Natera during the 2nd quarter worth approximately $322,000. Federated Hermes Inc. increased its holdings in shares of Natera by 13.6% during the second quarter. Federated Hermes Inc. now owns 480,745 shares of the medical research company’s stock worth $52,060,000 after purchasing an additional 57,476 shares during the period. Finally, Thoroughbred Financial Services LLC acquired a new stake in shares of Natera in the second quarter valued at approximately $1,380,000. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.